Literature DB >> 33634247

Roles of specific drug therapies for severe pulmonary arterial hypertension in palliative care: a case report.

Chi Yan Wong1, Kwok Wai Tsang1, Cho Wing Li1, Ho Yan Au1, Kwok Ying Chan1.   

Abstract

Pulmonary arterial hypertension (PAH) is an uncommon but potentially life-threatening illness. The elevated pulmonary arterial blood pressure will lead to right heart failure and even cardiopulmonary collapse if it is severe. Apart from general supportive measures, pulmonary hypertension-specific therapies (PHST) are available to slow down disease progression, but they are not curative. According to previous studies, many patients with severe PAH often had significant physical symptoms and psychological distress for both themselves and their families at the end of life. Moreover, they would have repeated admissions due to physical deterioration and decline in functioning associated with worsening in cardiac function. Some of these patients might suffer from unnecessary aggressive interventions and resuscitation because of lack of advance care planning discussion. As such, Palliative Care (PC) would be an important element as part of the overall management. Hereby, we reported a patient with severe PAH and schizoaffective disorder achieved good outcome from the use of combination PHST and PC input. Her physical and psychosocial needs could be addressed well by PC team. This case report showed the collaborative work between PC and parent teams. While parent team was able to manage the medical conditions related to PAH, however the physical and psychosocial needs should be addressed by PC team. More importantly, the PC team has essential roles of providing advance care planning discussions with the patient and help to reduce unnecessary interventions. Furthermore, PC would coordinate the community service to support her while staying at home. Roles of PHST will also be discussed in this case. Clinicians must take into account possible hemodynamic effects of any palliative intervention for PAH. 2021 AME Case Reports. All rights reserved.

Entities:  

Keywords:  Pulmonary hypertension; palliative care (PC); selexipag

Year:  2021        PMID: 33634247      PMCID: PMC7882262          DOI: 10.21037/acr-20-108

Source DB:  PubMed          Journal:  AME Case Rep        ISSN: 2523-1995


  19 in total

1.  An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Authors:  Raymond L Benza; Dave P Miller; Robyn J Barst; David B Badesch; Adaani E Frost; Michael D McGoon
Journal:  Chest       Date:  2012-08       Impact factor: 9.410

2.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report.

Authors:  James R Klinger; C Gregory Elliott; Deborah J Levine; Eduardo Bossone; Laura Duvall; Karen Fagan; Julie Frantsve-Hawley; Steven M Kawut; John J Ryan; Erika B Rosenzweig; Nneka Sederstrom; Virginia D Steen; David B Badesch
Journal:  Chest       Date:  2019-01-17       Impact factor: 9.410

4.  Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension.

Authors:  Ali Sadoughi; Kari E Roberts; Ioana R Preston; Ginny P Lai; Deborah H McCollister; Harrison W Farber; Nicholas S Hill
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

5.  Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: results of a cross-sectional survey.

Authors:  Eric R Fenstad; Tait D Shanafelt; Jeff A Sloan; Paul J Novotny; Louise A Durst; Robert P Frantz; Michael D McGoon; Keith M Swetz
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

6.  Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Olivier Sitbon; Richard Channick; Kelly M Chin; Aline Frey; Sean Gaine; Nazzareno Galiè; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Irene M Lang; Ralph Preiss; Lewis J Rubin; Lilla Di Scala; Victor Tapson; Igor Adzerikho; Jinming Liu; Olga Moiseeva; Xiaofeng Zeng; Gérald Simonneau; Vallerie V McLaughlin
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

7.  Drug-associated pulmonary arterial hypertension.

Authors:  Michael McGee; Nicholas Whitehead; Jennifer Martin; Nicholas Collins
Journal:  Clin Toxicol (Phila)       Date:  2018-03-06       Impact factor: 4.467

8.  Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension.

Authors:  Marius M Hoeper; Nazzareno Galié; Srinivas Murali; Horst Olschewski; Melvyn Rubenfire; Ivan M Robbins; Harrison W Farber; Vallerie McLaughlin; Shelley Shapiro; Joanna Pepke-Zaba; Joerg Winkler; Ralf Ewert; Christian Opitz; Volker Westerkamp; Jean-Luc Vachiéry; Adam Torbicki; Juergen Behr; Robyn J Barst
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

9.  Anxiety and depression in patients with pulmonary hypertension.

Authors:  Bernd Löwe; Kerstin Gräfe; Christiane Ufer; Kurt Kroenke; Ekkehard Grünig; Wolfgang Herzog; Mathias M Borst
Journal:  Psychosom Med       Date:  2004 Nov-Dec       Impact factor: 4.312

Review 10.  Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives.

Authors:  Loïc Guillevin; Iain Armstrong; Rino Aldrighetti; Luke S Howard; Henrik Ryftenius; Aryeh Fischer; Sandra Lombardi; Sean Studer; Pisana Ferrari
Journal:  Eur Respir Rev       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.